## SUPPLEMENTAL MATERIAL

| Genotype                  | Increase in AD (mm) | Increase in AD (%) | Phenotype   |
|---------------------------|---------------------|--------------------|-------------|
| WT                        | $0.82 \pm 0.01$     | $156 \pm 2$        | Susceptible |
| WT + CVF                  | $0.47 \pm 0.02$     | $90 \pm 4$         | Resistant   |
| C4 <sup>-/-</sup>         | $0.81 \pm 0.02$     | $163 \pm 5$        | Susceptible |
| $\mathrm{fB}^{-/-}$       | $0.51 \pm 0.02$     | $105 \pm 4$        | Resistant   |
| C5 <sup>-/-</sup>         | $0.70 \pm 0.06$     | $136 \pm 13$       | Susceptible |
| C3 <sup>-/-</sup>         | $0.67 \pm 0.05$     | $133 \pm 9$        | Susceptible |
| C3 <sup>-/-</sup> + C5aRA | $0.37 \pm 0.04$     | 78 ± 8             | Resistant   |

Supplementary Table I. AAA phenotype in complement-deficient mice

Mice underwent elastase perfusion in the absence or presence of CVF pre-treatment or C5aRA. Aortic diameter (AD) measurements were obtained prior to elastaste perfusion and increase in AD on day 14 is presented as absolute difference (in mm) or as % increase over pre-perfused measurements.